Radnor Woman Among First Patients in America to Receive New Treatment for Opioid Addiction

Radnor's Katie Burlingame laughs with Dr. Michael Frost of Conshohocken's Frost Medical Group. Photo courtesy of the Burlington County Times.
Photo of Probuphine courtesy of National Public Radio.
Photo of Probuphine courtesy of National Public Radio.

Local sufferers of opiate addition in long-term recovery programs are among the first in the country to gain access to a newly approved treatment option, according to a staff report from 6ABC.

Last month, the FDA approved Probuphine, a new implant type treatment for battling addiction. Among the first patients to receive the treatment was Radnor’s Katie Burlingame, who has been successfully fighting her addiction for nearly a decade.

“In August, I’ll be 10 years clean off any kind of opiates,” she said.

However, despite the success, the battle is ongoing, and she has to rely on medication to fight cravings. So far, she has been focusing on short term or dissolving tablets, but now she has decided to go with long-term option Probuphine.

According to Dr. Michael Frost of Conshohocken’s Frost Medical Group, Probuphine is delivered over six months through tiny rods that are inserted under the arm in a painless process. The medication is then released at a steady rate over a half-year period.

Dr. Frost and Burlingame agree that there is a pressing need for more addiction treatments.

“I feel like on a daily basis, I hear of someone dying,” she said. She thinks that Probuphine is a step in the right direction, and that it will help alleviate some fears of people who are just starting with recovery.

Read more about the treatment at 6ABC by clicking here.

Join Our Community

Never miss a Delaware County story!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.